Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer
- 1 July 2001
- Vol. 58 (1) , 59-64
- https://doi.org/10.1016/s0090-4295(01)01011-1
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Weekly 1-hour infusion of paclitaxelCancer, 2000
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 1999
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- Cancer phase I clinical trials: efficient dose escalation with overdose controlStatistics in Medicine, 1998
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.Journal of Clinical Oncology, 1997
- Paclitaxel-induced neuropathyAnnals of Oncology, 1995
- Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology groupCancer, 1993
- Preclinical and clinical perspectives on the use of estramustine as an antimitotic drugPharmacology & Therapeutics, 1992
- Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1992
- Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic CancerJournal of Urology, 1992